Inventor · disambiguated record
Mark Allen Abrams
Also filed as: ABRAMS MARK · ABRAMS MARK A · ABRAMS MARK ALLEN
26 granted patents·9 pending applications·545 citations·filing 1993–2004
97Inventor score
Top patents by PatentIndex Score
35 records- 0191US5858347ATherapeutic methods using fusion proteins between interleukin-3 (IL-3) variants and other hematopoietic factorsSEARLE & CO·Filed 1995·Granted Jan 12, 1999·83 cites·53 claims
- 0288US6440407B1Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 (IL-3) multiple mutation polypeptidesSEARLE & CO·Filed 1996·Granted Aug 27, 2002·37 cites·24 claims
- 0388US5997860AEx-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokinesSEARLE & CO·Filed 1995·Granted Dec 7, 1999·68 cites·44 claims
- 0483US6030812AFusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factorsSEARLE & CO·Filed 1995·Granted Feb 29, 2000·47 cites·66 claims
- 0581US5772992ACompositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factorsSEARLE & CO·Filed 1994·Granted Jun 30, 1998·36 cites·23 claims
- 0680US5677149AInterleukin-3 (IL-3) mutant polypeptides and their recombinant productionSEARLE & CO·Filed 1993·Granted Oct 14, 1997·27 cites·97 claims
- 0778US6361977B1Methods of using multivariant IL-3 hematopoiesis fusion proteinFiled 1995·Granted Mar 26, 2002·33 cites·62 claims
- 0874US6074639AEx vivo expansion of hematopoietic cells using interleukin-3 (IL-3) variant fusion proteinsSEARLE & CO·Filed 1995·Granted Jun 13, 2000·20 cites·60 claims
- 0974US6022535ATreatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factorsSEARLE & CO·Filed 1995·Granted Feb 8, 2000·21 cites·62 claims
- 1074US5604116AInterleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methodsSEARLE & CO·Filed 1993·Granted Feb 18, 1997·20 cites·31 claims
- 1172US6057133AMultivariant human IL-3 fusion proteins and their recombinant productionSEARLE & CO·Filed 1994·Granted May 2, 2000·22 cites·70 claims
- 1272US5738849AInterleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising themSEARLE & CO·Filed 1994·Granted Apr 14, 1998·23 cites·44 claims
- 1371US6436387B1Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteinsSEARLE & CO·Filed 1996·Granted Aug 20, 2002·19 cites·48 claims
- 1470US6132991AHuman interleukin-3 (IL-3) variant fusion proteinsSEARLE & CO·Filed 1995·Granted Oct 17, 2000·15 cites·60 claims
- 1569US2005244372A1Interleukin-3 (IL-3) multiple mutation polypeptidesBAUER S C·Filed 2004·Application pending·0 cites
- 1665US6051217ATherapeutic uses of interleukin-3 (IL-3) multiple mutation polypeptidesSEARLE & CO·Filed 1995·Granted Apr 18, 2000·15 cites·132 claims
- 1763US2003103936A1Method of ex-vivo expansion of hematopoeitic cells using interleukin-3 (IL-3) multiple mutation polypeptidesFiled 2002·Application pending·0 cites
- 1861US6060047ACo-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell productionSEARLE & CO·Filed 1995·Granted May 9, 2000·16 cites·31 claims
- 1961US2003220472A1Interleukin-3 (IL-3) multiple mutation polypeptidesFiled 2002·Application pending·0 cites
- 2058US6153183ACo-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell productionSEARLE & CO·Filed 1994·Granted Nov 28, 2000·15 cites·33 claims
- 2158US6093395ACo-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell productionSEARLE & CO·Filed 1995·Granted Jul 25, 2000·14 cites·56 claims
- 2255US2003165461A1Methods of ex-vivo expansion of hematopoeitic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factorsFiled 2002·Application pending·0 cites
- 2355US2005059149A1Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteinsFiled 2004·Application pending·0 cites
- 2454US2003185790A1Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteinsFiled 2002·Application pending·0 cites
- 2553US2003194783A1Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell productionFiled 2002·Application pending·0 cites
- 2644US6413509B1Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factorsFiled 1996·Granted Jul 2, 2002·3 cites·35 claims
- 2740US6361976B1Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell productionFiled 1995·Granted Mar 26, 2002·2 cites·38 claims
- 2839US6479261B1Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cellsPHARMACIA CORP·Filed 1995·Granted Nov 12, 2002·2 cites·22 claims
- 2936US6379662B1Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell productionFiled 1995·Granted Apr 30, 2002·2 cites·10 claims
- 3034US6458931B1Interleukin-3 (IL-3) multiple mutation polypeptidesFiled 1995·Granted Oct 1, 2002·1 cites·36 claims
- 3134US2004018618A1Interleukin-3 (IL-3) mutant polypeptidesFiled 2002·Application pending·0 cites
- 3233US7091319B1IL-3 variant hematopoiesis fusion proteinBAUER S CHRISTOPHER·Filed 1995·Granted Aug 15, 2006·2 cites·36 claims
- 3332US5997857ACo-administration of interleukin-3 mutants with colony stimulating factorsSEARLE & CO·Filed 1995·Granted Dec 7, 1999·0 cites·50 claims
- 3431US6403076B1Compositions for increasing hematopoiesis with interleukin-3 mutantsFiled 1995·Granted Jun 11, 2002·2 cites·22 claims
- 3530US2003219843A1Methods of diagnosing and treating abnormal growthFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Allen Abrams files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →